Stocktoria
HCW Biologics Inc. HCWB
HCW Biologics Inc. (HCWB) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $54,232 at a -14677.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -0.27 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HCWB | HCW Biologics Inc. | 2/9 | — | — | — |
| AVTX | Avalo Therapeutics, Inc. | 1/9 | -8.95 | — | — |
| CNTB | Connect Biopharma Holdings Ltd | 1/9 | — | — | -99.8% |
| INO | INOVIO PHARMACEUTICALS, INC. | — | — | — | — |
| ALT | Altimmune, Inc. | 4/9 | 0.63 | — | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | 1/9 | — | — | — |
| AXIM | AXIM BIOTECHNOLOGIES, INC. | 3/9 | — | — | — |
About HCW Biologics Inc.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
FAQ
Is HCWB financially healthy?
HCW Biologics Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does HCWB pay a dividend?
No, HCW Biologics Inc. does not currently pay a dividend.
How profitable is HCWB?
In FY2025, HCW Biologics Inc. had a net margin of -14677.1% and a return on equity of -287.9%.
What is the analyst price target for HCWB?
The average Wall-Street price target for HCW Biologics Inc. is $30.00, about 853.9% above the recent price, from 1 analysts (consensus: buy).
Is HCWB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on HCW Biologics Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.